


## Data Sheet

[WWW.UREIKO-CHEM.COM](http://WWW.UREIKO-CHEM.COM)

Global Supplier of Chemical Probes, Inhibitors & Agonists

<b>Product Name</b>	: IL-17 modulator 4
<b>Cat.No.</b>	: URK-V2488
<b>CAS No.</b>	: 2446803-65-0
<b>Molecular Formula</b>	: $C_{27}H_{34}N_6O_2$
<b>Molecular Weight</b>	: 4744.60
<b>Target</b>	:
<b>Solubility</b>	:



### Biological Activity

IL-17 modulator 4 is a small molecule inhibitor that targets the interleukin-17 (IL-17) pathway.

IL-17 modulator 4 inhibits the IL-17 pathway by selectively blocking the interaction between Act1 and IL-17R, thereby preventing the recruitment of downstream signaling proteins and the subsequent activation of proinflammatory pathways. IL-17 modulator 4 has been shown to have a high degree of selectivity for the IL-17 signaling pathway, with no significant effects on other cytokine signaling pathways.

IL-17 modulator 4 targets the IL-17 pathway by selectively inhibiting the activity of IL-17 signaling proteins. The IL-17 pathway is initiated by the activation of IL-17 receptors (IL-17R) on the surface of target cells, such as epithelial cells and fibroblasts. IL-17R activation leads to the recruitment of a number of signaling proteins, such as Act1 and TRAF6, which ultimately activate downstream signaling pathways, such as NF- $\kappa$ B and MAPK, leading to the expression of proinflammatory cytokines.

IL-17 modulator 4 inhibits the IL-17 pathway by selectively blocking the interaction between Act1 and IL-17R, thereby preventing the recruitment of downstream signaling proteins and the subsequent activation of proinflammatory pathways. IL-17 modulator 4 has been shown to have a high degree of selectivity for the IL-17 signaling pathway, with no significant effects on other cytokine signaling pathways.

### References

1. Dan, Y. et al. (2018). Small-molecule Targeting of IL-17 Signaling for the Treatment of Inflammatory Diseases. *Cell Chemical Biology*, 25: 1350-1360.e5.
2. Xie, Y. et al. (2017). Small-molecule Inhibitor Targeting the IL-17 Signaling Pathway Improves Multiple Parameters of Psoriasis-like Skin Disease in Mice. *Journal of Pharmacology and Experimental Therapeutics*, 361: 303-311.

*Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!*

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

[JACK@UREIKO-CHEM.COM](mailto:JACK@UREIKO-CHEM.COM)